John L. Marshall

Vince Lombardi Cancer Clinic

Full Professor(heuristic)

Colorectal Cancer Treatments and Studies · Oncology

h-index84

i10-index275

Publications834

Citations26,824

Grants

18 total · 0 active

NIH #5M01RR023942-03

CLINICAL TRIAL: PHASE 1 CLINICAL TRIAL OF DAILY ORAL GLEEVE AND ONE HOUR WEEKLY

Amount: $NaNK
Period: 2009-04-01 → 2010-03-31
PIs: 1
Est. capacity / PI: ~ students

Awarded at GEORGETOWN UNIVERSITY

NIH #5M01RR023942-02

CLINICAL TRIAL: PHASE 1 CLINICAL TRIAL OF DAILY ORAL GLEEVE AND ONE HOUR WEEKLY

Amount: $NaNK
Period: 2008-04-01 → 2009-03-31
PIs: 1
Est. capacity / PI: ~ students

Awarded at GEORGETOWN UNIVERSITY

NIH #1M01RR023942-01

VACCINIA-CEA(6D)TRICOM & FOWLPOX-CEA(6D)-TAXOTERE W/GM-CSF & DOCETAXEL

Amount: $NaNK
Period: 2007-05-01 → 2008-03-31
PIs: 1
Est. capacity / PI: ~ students

Awarded at GEORGETOWN UNIVERSITY

Student capacity is a rough estimate from remaining award size, split equally among PIs. Actual funding decisions vary.

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

Potential Collaborators

Recent Publications

Last 2 years · showing 20 of 44

Implementing an electronic health record workflow to identify parents with cancer and implications for supportive oncology care
Supportive Care in Cancer · 2026-04-21
Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer
UNC Libraries · 2026-04-18
Correlates and Detection of Digital Health Literacy in Patients With Colorectal Carcinoma or Non-Hodgkin Lymphoma: Cross-Sectional Study
JMIR Cancer · 2025-11-14 · 1 citations
795P Optimizing immunotherapy in mismatch repair-deficient colorectal cancer through tailored, subtype-specific treatment approaches
Annals of Oncology · 2025-09-01
A phase II single-arm study of combination pembrolizumab and olaparib in the treatment of patients with advanced biliary tract cancer
npj Precision Oncology · 2025-07-08 · 2 citations
259MO BXCL701 plus pembrolizumab in second-line advanced pancreatic ductal adenocarcinoma
Annals of Oncology · 2025-07-01
AI enabled exome and transcriptome liquid biopsy platform spanning the continuum of care in oncologyPreprint
medRxiv · 2025-05-28
Supplementary Figure S6 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed TherapyPreprint
2025-04-03
Supplementary Figure S2 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed TherapyPreprint
2025-04-03
Supplementary Figure S5 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed TherapyPreprint
2025-04-03
Supplementary Figure S3 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed TherapyPreprint
2025-04-03
Supplementary Table S1 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy
2025-04-03
Supplementary Figure S8 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed TherapyPreprint
2025-04-03
Supplementary Figure S1 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed TherapyPreprint
2025-04-03
Supplementary Table S3 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy
2025-04-03
Supplementary Table S2 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy
2025-04-03
Supplementary Figure S7 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed TherapyPreprint
2025-04-03
Supplementary Fiugre S4 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed TherapyPreprint
2025-04-03
Rethinking the rise of early-onset gastrointestinal cancers: a call to action
JNCI Cancer Spectrum · 2025-01-03 · 11 citations
<div> Tuning In, Voting Out: News Consumption Cycles, Homicides, and Electoral Accountability in Mexico</div>Preprint
SSRN Electronic Journal · 2025-01-01

Open author page on OpenAlex →

John L. Marshall

Grants

CLINICAL TRIAL: PHASE 1 CLINICAL TRIAL OF DAILY ORAL GLEEVE AND ONE HOUR WEEKLY

CLINICAL TRIAL: PHASE 1 CLINICAL TRIAL OF DAILY ORAL GLEEVE AND ONE HOUR WEEKLY

VACCINIA-CEA(6D)TRICOM & FOWLPOX-CEA(6D)-TAXOTERE W/GM-CSF & DOCETAXEL

All Grants

CLINICAL TRIAL: PHASE 1 CLINICAL TRIAL OF DAILY ORAL GLEEVE AND ONE HOUR WEEKLY

CLINICAL TRIAL: PHASE 1 CLINICAL TRIAL OF DAILY ORAL GLEEVE AND ONE HOUR WEEKLY

VACCINIA-CEA(6D)TRICOM & FOWLPOX-CEA(6D)-TAXOTERE W/GM-CSF & DOCETAXEL

TRICOM + TAXOTERE

CEA BASED VACCINE THERAPY IN PATIENTS WITH ADVANCED CA

TRICOM + TAXOTERE

CEA BASED VACCINE THERAPY IN PATIENTS WITH ADVANCED CA

CEA BASED VACCINE THERAPY IN PATIENTS WITH ADVANCED CA

CEA BASED VACCINE THERAPY IN PATIENTS WITH ADVANCED CA

CEA BASED VACCINE THERAPY IN PATIENTS WITH ADVANCED CA

CALGB 89903: PH II OF ANTI-IDIOTYPE MONOCLONALANTIBODY VACCINE CEAVAC & TRIAB

Daily oral Gleevec and 1hr weekly Paclitaxel infusion

PKC MODULATION IN PATIENTS WITH ADVANCED CANCER

CEA BASED VACCINE THERAPY OF CEA BEARING TUMORS

CEA BASED VACCINE THERAPY OF CEA BEARING TUMORS

PKC MODULATION IN PATIENTS WITH ADVANCED CANCER

PKC MODULATION IN PATIENTS WITH ADVANCED CANCER

PKC MODULATION IN PATIENTS WITH ADVANCED CANCER

Career Trajectory

Research Cluster Map

Potential Collaborators

Recent Publications